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Abstract
Background: The oral cavity is a common site of complications related to the cytotoxic effect of high-dose chemotherapy and
radiation therapy. Considering our limited understanding of the burden of illness in the oral cavity from various cytotoxic therapies,
it is difficult to produce evidence-based, preventive and management protocols. A prospective multicenter study is necessary to
collect data on the burden of illness from various cytotoxic regimens.
Objective: The objectives of this prospective international observational multicenter study in hematopoietic stem cell transplant
(HSCT) patients are to establish the nature, incidence and temporal relationship of oral complications related to conditioning
regimens (chemotherapy with or without total body irradiation), stem cell transplantation and the immunologic reactions (mainly
graft-vs-host-disease) that may follow, and to determine what subjective and objective oral complications related to treatment
can predict negative clinical and economic outcomes and reduced quality of life.
Methods: Adult patients at six study sites receiving full intensity conditioning, reduced intensity conditioning or nonmyeloablative
conditioning, followed by autologous or allogeneic hematopoietic stem cell infusion, are included. A pre-treatment assessment
includes medical conditions, planned chemo- and radiation therapy regimen, medications, allergies, social history, patient report
of oral problems, dental history, subjective oral complaints, objective measures of oral conditions, current laboratory values,
dental treatment recommended and untreated dental disease. Starting 1-3 days after hematopoietic stem cell infusion, a bedside
assessment is completed 3 days per week until resolution of neutropenia. A patient questionnaire is also completed during
hospitalization. Beyond this time, patients with continued oral mucositis or other oral problems are followed 1 day per week in
an inpatient or outpatient setting. Additional visits for urgent care for acute oral problems after hospitalization are documented.
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Autologous transplant patients are being followed up at 100 days (SD 30 days) and at 1 year (SD 30 days) post-transplantation
to identify any long-term side effects. Patients treated with allogeneic transplantation are being followed at 100 days (SD 30
days), 6 months (SD 30 days), and 12 months (SD 30 days). The follow-up assessments include cancer response to therapy,
current medical conditions, medications, subjective and objective oral findings, quality of life measures and laboratory values.
The targeted enrollment is 254 patients who have received HSCT.
Results: A total of 260 participants have been enrolled, with 233 (91%) who have received HSCT. We anticipate enrollment
of 20-30 additional participants to obtain the sample size of 254 enrolled participants who have received HSCT.
Conclusions: The results of the ongoing prospective study will provide a unique dataset to understand the impact of oral
complications on patients undergoing HSCT and provide needed evidence for guidelines regarding the management of this patient
cohort.
(JMIR Res Protoc 2018;7(4):e103)   doi:10.2196/resprot.8982
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Introduction
The annual incidence of cancer is 11 million cases worldwide
[1]. Early cancer detection and advances in cancer therapies
have provided important management advances to improve
survival, and quality of life (QOL) in later years. Common
cancer treatment strategies include surgical resection,
chemotherapy (CT), radiotherapy (RT), and hematopoietic stem
cell transplantations (HSCT). The goal of such treatments is to
eliminate all cancer cells. However, side effects from these
therapies can limit the effectiveness of treatment and have a
marked impact on the patient’s QOL. The oral cavity is a
common site of complications related to cytotoxic therapies.
The Surgeon General’s report on Oral Health in America
estimates that more than 400,000 patients in the US undergoing
cancer treatment will develop oral complications annually [2].
The report calls for more science and the effective translation
of science to improve oral health and establish clinical practice
guidelines based on a higher quality science base.
Recommendations are needed to effectively transfer research
findings in the field of oncology, including oral complications
seen with cancer therapies, and oral management prior to the
start of cancer therapy, to public and health professionals. Well
developed, evidence-based management recommendations have
the potential to enhance the appropriateness of clinical practice,
improve the quality of oral health care, lead to better patient
outcomes, and identify areas of further research needs. To
effectively change perceptions of the burden of illness of oral
complications from cancer therapies, a complete understanding
of the impact of these complications is vital. Underestimating
the impact of oral complications may result in avoidance or
delay in appropriate care for cancer patients.
Numerous preventive care protocols have been proposed to
minimize oral complications from cancer therapies.
Unfortunately, these protocols are rarely evidence-based and
often rely on “expert opinion” or anecdotes. The lack of
well-controlled, prospective studies is the primary reason for
the limitation in preventive and management protocols. The
Institute of Medicine (IOM) report determined that insufficient
systematic research is available to assess the prevention and
management of the oral problems associated with head and neck
cancer, leukemia, and lymphoma [3].
Considering our limited understanding of the burden of illness
in the oral cavity from various cancer therapies, it is difficult to
produce evidence-based, preventive and management protocols.
Therefore, a prospective multicenter study is necessary to collect
data on the burden of illness from various cancer regimens.
The literature reports a wide range of oral complications with
varying incidences. Oral mucositis, or inflammation of the
mucosal surfaces, sometimes also called mucosal barrier injury
(MBI), is a major dose-limiting side effect of chemo- and
radiation therapy, specifically conditioning therapy before
HSCT. Severe mucositis has been associated with pain,
infection, poor nutrition, increased hospitalization and a major
impact on QOL and economic outcomes. Other reported
complications are bleeding, dysphagia (difficulty swallowing),
dysgeusia (altered sensation of taste), infection (bacterial, viral,
and fungal), pain, trismus, medication-related osteonecrosis of
the jaw, osteoradionecrosis, xerostomia/salivary gland
dysfunction, caries, periodontal disease, and
graft-vs-host-disease (GVHD) [4]. Recent systematic reviews
of these oral complications have confirmed the limitations in
knowledge of the incidence and severity of the various additive
oral complications [5]. Additionally, based on these systematic
reviews, prevention and management protocols are very limited
in quality and design such that it is difficult to produce
evidence-based protocols leading to a significant gap in
treatment protocols for this patient population. Furthermore,
how these common oral complications impact clinical and
economic outcomes and affect (QOL) is poorly understood [6].
The goal of the present study is to bridge these research gaps
by way of a well-designed, prospective, multicenter
observational study.
The objectives of this prospective international observational
multicenter study in HSCT patients is to determine the relevant
factors that may predict negative clinical and economic
outcomes through the following methods and approaches. We
will establish the nature, incidence and temporal relationship
of oral complications related to conditioning regimens
(chemotherapy with or without total body irradiation, HSCT
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and the immunologic reactions (mainly chronic GVHD) that
may follow, and to determine what subjective and objective
oral complications related to treatment can predict negative
clinical and economic outcomes and reduced QOL.
The purpose of this manuscript is to describe the study protocol
for this important ongoing multi-center study and to report the
current sites and enrollment.
Methods
Study Design
The present study aims to address research gaps regarding the
impact of oral complications in HSCT patients by way of a
well-designed prospective, longitudinal, international,
observational, multicenter cohort study of patients receiving
conditioning regimens followed by HSCT (autologous or
allogeneic). Data collected from this study will allow a
comprehensive understanding of the burden of illness of oral
complications related to type of conditioning therapy and
provide a clearer understanding of prevention and management
protocols for oral complications in HSCT patients.
Outcome Measures
To address the primary aim of determining the incidence,
severity and temporal relationship of oral complications related
to type of conditioning regimen, we register demographics (age,
sex), diagnosis, cytotoxic therapy and assess the following
outcomes (details are provided in Multimedia Appendix 1):
• Subjective oral complications: Oral pain, xerostomia (dry
mouth), dysgeusia (taste changes) and dysphagia
(swallowing difficulties);
• Objective oral complications: Oral mucositis,
hyposalivation, oral infections (viral, fungal, bacterial),
submucosal hemorrhage, dental and periodontal diseases
and complications, osteonecrosis, and GVHD.
To address the secondary aims of determining what factors can
predict negative clinical and economic outcomes and reduced
QOL, we assess the following:
• Antimicrobial prophylaxis or Keratinocyte Growth Factor
medication and ongoing immunosuppression for GVHD
• Institutional standard of care preventative and management
protocols
• Nausea or vomiting, diarrhea, fever, weight and blood
values
• Additional hospital visits, prolonged hospital stays, systemic
infection, increased medication/treatment (eg antibiotics,
opioids), poor nutrition or parenteral nutrition and death.
• Subjective measures of oral pain, xerostomia, dysgeusia
and dysphagia, and a feeling of well-being. To minimize
the length of time needed to participate in the present study,
generic oral health-related quality of life measures (eg,
OHIP-14) were not used and instead QOL questions were
focused on subjective areas related to oral complications
from cancer therapy.
• Genomic factors (Multimedia Appendix 2).
Study Organization
Subjects are enrolled at six clinical study sites: Sahlgrenska
University Hospital, Gothenburg, Sweden; Karolinska
University Hospital Huddinge, Stockholm, Sweden; Carolinas
Medical Center, Charlotte, NC, USA; BC Cancer, Vancouver,
BC, Canada; Academic Medical Center, Amsterdam, The
Netherlands; Radboud University Medical Center, Nijmegen,
The Netherlands. Study personnel at each site include the site
principal investigator, study coordinator(s), and clinical
examiner(s). The Data Coordinating Center for the study is
located at the Carolinas HealthCare Systems, Charlotte, NC,
USA.
Safety of Human Subjects and Data Integrity
Approval from the research ethics board at each clinical study
site was obtained prior to enrollment. Sites were approved to
start enrollment after a site visit was completed by the study
principal investigators (IVB, MTB) to ensure appropriate
infrastructure, patient population, research staffing, calibration
of research personnel of the study design, data management and
study outcomes. Informed consent is obtained from each study
participant prior to inclusionStudy data is entered into MedView,
which is a computer program that is based on formalized input
and registration of all clinical information. MedView provides
a suite of tools for formalizing, gathering, and analyzing data.
MedView is aimed at clinical research and is well suited for
multicenter studies [7]. MedView program is accessible on the
Internet. Each participating center is provided with a unique
username and password. Data sent over the internet are
encrypted. No personal identifiers are included. Study data is
loaded into a secure database at University of Gothenburg,
Sweden. Staff from the Data Coordinating Center monitors
validation of the study data to identify missing data or forms or
incorrect registrations and communicates this information with
each enrollment site to resolve any problems.
Training and Calibration
All study personnel receive training on the parameters needed
to conduct this study which includes training on clinical
assessments; training on completing study forms, data entry and
all non-clinical procedures. In addition, annual calibration on
objective clinical measures is conducted for all clinical
examiners.
Subject Selection Criteria
Inclusion Criteria
Adult patients receiving full intensity conditioning, reduced
intensity conditioning or nonmyeloablative conditioning,
followed by hematopoietic stem cell infusion (autologous or
allogeneic) are eligible for inclusion. For diagnoses, see Textbox
1.
Exclusion Criteria
Patients unable to give consent are not eligible for inclusion.
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Textbox 1. Patients with the following diagnoses to go through hematopoietic stem cell transplantations (HSCT) are eligible for inclusion.
For allogeneic transplant:
Acute leukemia
Myelodysplastic syndrome
Aplastic anemia
Lymphoma including chronic lymphocytic leukemia
Chronic myeloid leukemia
Myelofibrosis
Other conditions being managed with HSCT
For autologous transplant:
Multiple myeloma
Lymphoma including chronic lymphocytic leukemia
Testicular cancer
Autoimmune diseases (scleroderma; systemic sclerosis)
Other conditions being managed with HSCT
Figure 1. Study flow diagram.
Study Assessments
Patients who meet the enrollment criteria are approached and
consent is reviewed and obtained. A pretreatment assessment
(Phase I and II) is completed to include the following: medical
conditions, planned chemo- and radiation conditioning therapy
regimen, medications, allergies, social history, patient report of
oral problems, dental history, subjective oral complaints,
objective measures of oral conditions, current laboratory values,
dental treatment recommended and untreated dental disease.
This pretreatment assessment will occur up to 8 weeks prior to
stem cell transplantation (Figure 1).
Study Flow Diagram
A bedside assessment (Phase III) will be completed 3 days per
week (Monday, Wednesday, Friday) starting day +1, +2 or +3
after transplantation (day 0) depending on which day of the
week the transplantation occurs, until resolution of neutropenia
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(ie, absolute granulocyte count > 0.5 x 109/l). For patients with
continued mucositis or other oral problems requiring
hospitalization after resolution of neutropenia, an oral
examination will be completed for up to 6 weeks duration. A
patient questionnaire will be completed for each study visit to
the patient (Monday, Wednesday, Friday) during the patient
hospitalization. Beyond this time, patients with continued oral
mucositis or other oral problems will be followed 1 day per
week (Phase IV) in an inpatient or outpatient setting.
Additional visits for urgent care for acute oral problems will be
documented regarding the nature of the oral problem and
treatment provided (Phase IV). This will be documented for up
to 6 months for the autologous stem cell transplantation patients
and 12 months for the allogeneic transplant patients.
For long-term follow-up, patients with autologous
transplantation will be followed-up as part of standard of care
visits. The first follow-up visit (Phase V) in an outpatient setting
will occur 100 days (SD 30 days). The patients will also
complete the patient questionnaire at 100 days (SD 30 days).
These patients will also receive a questionnaire (Phase VI) by
mail at 1 year (SD 30 days) posttransplantation to identify any
long-term side effects . Patients with allogeneic transplantation
will also be followed up as part of standard of care visits (Phase
V) in an outpatient setting at 100 days (SD 30 days), as well as
after 6 months (SD 30 days), and 12 months (SD 30 days), at
which time the patient questionnaire is also completed. The
follow-up assessments will include cancer response to therapy,
current medical conditions, medications, subjective and objective
oral findings, QOL measures and laboratory values. For the
study outline of the standardized examination process, see Figure
1. If a patient is deceased, it will be noted (Phase VII).
Statistical Considerations
Analyses for establishing the nature of oral complications will
be primarily descriptive in nature using percentages and rates
with corresponding confidence intervals. Analyses to determine
what oral complications related to treatment can predict negative
outcomes will use inferential statistics comparing those with
oral complications to those without. For each outcome,
univariate analysis will use Student’s t-test (or Wilcoxon Rank
Sum) for continuous measures and chi-square or Fisher’s exact
tests for dichotomous variables with a critical value of 0.05.
Additional potential risk factors that are thought to have
prognostic value will first be analyzed by univariate analysis
and appropriate variables (P<0.1) will be considered as
confounders in multivariable modeling (either linear or logistic
regression depending on the outcome distribution).
Table 1. Expected incidence of oral complications after HSCT and estimated sample size required to reach a statistical significance level of 95%.
GVHD: graft-vs-host-disease.
Precision (%)Sample sizeExpected incidence (%)Estimate sourceOral complication
+/– 623765Preliminary studyMucositis
+/– 8133
+/– 1083
+/– 624440[8]Xerostomia
+/– 8140
+/– 1086
+/– 625145[9]Oral pain
+/– 8148
+/– 1091
+/– 625254Preliminary literature reviewDysphagia
+/– 8139
+/– 1093
+/– 662-2527-54[10]Chronic GVHD
+/– 624638Preliminary studyDysgeusia
+/– 8133
+/– 1088
+/– 625443[11]Oral viral
+/– 8148
+/– 1093
+/– 625238[12]Oral fungal
+/– 8142
+/– 1091
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Adjusted differences in means or adjusted odds ratios and
corresponding confidence intervals will be calculated to
represent measures of association. Analyses will be performed
with the SAS Enterprise Guide version 6.1 (SAS Institute Inc,
Cary, North Carolina, USA).
Sample Size
The primary aim of the study is to establish the nature, incidence
and temporal relationship of oral complications related to
conditioning regimen. The source of the expected incidences is
included in Table 1. These samples sizes were determined with
alpha of .05 and differing levels of acceptable absolute precision.
The range of sample size estimates for the various oral
complications ranged from 62-254 depending on the incidence
estimate and precision level. Using the most conservative
estimate, a total of 254 patients will need to be assessed for oral
complications during stem cell transplantation to obtain 6%
precision for the main oral complications listed in Table 1. Thus,
to account for participants that do not make it to stem cell
transplant (approximately 10%) and to ensure sufficient patients
are assessed to allow for differences in enrollment sites, we will
enroll up to 320 patients. The present study is a prospective,
observational registry, with no interventional component. We
anticipate that there will be differences in approach to oral
prevention and management protocols per treatment center. This
will provide an opportunity to describe the impact of different
management regimens on Ora-Stem outcomes. The study was
not originally powered for these differences; thus, this data may
be more preliminary in nature, but still provide a robust dataset
to explore differences in enrollment sites.
Results
To date, 91% of a targeted number of participants have been
enrolled with 233 participants receiving an HSCT. We anticipate
enrollment of at least 20-30 additional participants to ensure
254 enrolled patients receive a HSCT, which will be completed
by June 2018.
A preliminary analysis completed October 30, 2017 of 222
enrolled participants demonstrated the most common medical
diagnoses managed with HSCT included: multiple
myeloma=34%; acute myelogenous leukemia=22%;
lymphoma=15%, and acute lymphocytic leukemia=6% with
53% managed by allogeneic transplantation. Preliminary
assessment of oral complications demonstrated approximately
32% of all participants experienced a grade 2 or higher mucositis
during hospitalization and at least 39% of allogeneic HSCT
patients have developed oral GVHD (this is an underestimation
as not all patients have completed a follow-up visit).
Discussion
Rationale
Numerous oral complications have been associated with
cytotoxic therapies. To establish recommendations for pre-,
interim-, and postcancer therapy management of oral problems
in patients receiving high dose conditioning regimen and HSCT
(autologous or allogeneic), an understanding of the scope of
oral complications from HSCT must be established and be
related to time after treatment and treatment regimen. The lack
of clarity in this field is reflected in a lack of comprehensive
and effective oral management regimens in the clinical arena.
With a deeper understanding of oral complications, oral care
regimens to minimize such complications can be appropriately
formulated and evaluated. There is thus a pressing need to
establish the nature, incidence and temporal relationship of oral
complications related to conditioning therapies, as well as other
types of chemo- and radiation therapies.
Limitations
To optimize the data quality and generalizability of the present
study, a prospective, multicenter design was planned. Due to
limitations in research infrastructure, it was not possible to
consecutively enroll patients at every site. Although patients
are not consecutively enrolled due to logistical limitations of
enrollment of all possible patients; deliberate efforts to ensure
high data quality from patients who were enrolled will allow
for a robust dataset. We have also tracked and will report on all
patients that could have been enrolled and the reason they were
not enrolled. Additionally, the current study is observational in
nature only and thus relies on institutional standard of care
preventative and management protocols. This will allow for
comparisons of the different treatment protocols between the
enrollment sites. The design of this study is purposefully not
an interventional study to allow for this comparison of standard
of care protocols, thus definitive data on effectiveness of
protocols will not be possible with this study design but will be
instrumental in the design of future interventional studies.
Conclusions
The results of the ongoing prospective study will provide a
unique dataset to understand the impact of oral complications
on patients undergoing HSCT and provide needed information
with forming more evidence-based guidelines regarding the
management of this patient cohort.
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